China (Mainland)
Supply High quality Prasugrel powder //CAS: 150322-43-3 CAS NO.150322-43-3
- FOB Price: USD: 1.00-1.00 /Metric Ton Get Latest Price
- Min.Order: 1 Metric Ton
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Available Specifications:
Pharma Grade (1-100)Metric TonPharma Grade (1-1000)Metric TonPharma Grade (1-10)Metric Ton
- Product Details
Keywords
- Supply High quality Prasugrel powder //CAS: 150322-43-3
- Prasugrel powder
- CAS 150322-43-3
Quick Details
- ProName: Supply High quality Prasugrel powder /...
- CasNo: 150322-43-3
- Molecular Formula: C20H20FNO3S
- Appearance: WhitePowder
- Application: pharmaceutical intermediates
- DeliveryTime: within 5-7 days after payment
- PackAge: 25kg/ drum, or as your requirements
- Port: Shanghai port
- ProductionCapacity: 100 Metric Ton/Month
- Purity: 99%min
- Storage: regualr storage
- Transportation: By air、ship and courier
- LimitNum: 1 Metric Ton
- Related Substances: undetected
- Residue on Ignition: less than 0.05%
- Heavy Metal: less than 0.02%
- Valid Period: 3 years
- EINECS: 200-659-6
- Application: Pharm Intermediates
- Appearance: WhitePowder
- Molecular Weig: 373.44
- Melting point: 184°C
- Brand: zhishang
- Product name: Prasugrel
- HPLC: available
- NMR: available
Superiority
Details
Supply High quality Prasugrel powder //CAS: 150322-43-3
prasugrel intermediate
1.Prasugrel hcl
2.Used as cardiovascular drug
3.Supplly with competitive price
prasugrel medicine grade
|
Items |
Specifications |
Results |
|
Appearance |
White powder |
White powder |
|
Assay( on dried, HPLC) |
≥99.0% |
99.3% |
|
Related substance |
Conforms |
Conforms |
|
Heavy Metal( as Pb) |
≤0.002% |
<0.002% |
|
Loss on drying |
≤0.2% |
Conforms |
Prasugrel is a novel platelet inhibitor developed by Daiichi Sankyo Co. and produced by Ube and currently marketed in the United States in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). Prasugrel was approved for use in Europe in February 2009, and is currently available in the UK. On July 10, 2009, the US Food and Drug Administration approved the use of prasugrel for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI
